Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6153 |
Icotinib
BPI-2009,埃克替尼,BPI-2009H,Conmana |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Icotinib (Conmana) 是一种口服的基于喹唑啉的表皮生长因子受体 (EGFR) 抑制剂,IC50值为5 nM,具有潜在的抗肿瘤活性。 | |||
T2307 |
Icotinib Hydrochloride
埃克替尼盐酸盐,盐酸埃克替尼,BPI-2009H |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Icotinib Hydrochloride (BPI-2009H) 是一种口服的基于喹唑啉的表皮生长因子受体 (EGFR) 抑制剂,IC50值为5 nM,具有潜在的抗肿瘤活性。 | |||
T15199 |
Edicotinib
JNJ-527,JNJ-40346527 |
c-Fms; FLT; CSF-1R; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Edicotinib (JNJ-527) 是能够透过血脑屏障的、口服具有活性的、选择性的CSF-1R 抑制剂 (IC50:3.2 nM)。它对 KIT (IC50:20 nM) 和 FLT3 (IC50:190 nM) 的抑制作用较小。它抑制小胶质细胞的扩张,减弱小胶质细胞的增殖和神经退行性变。它可用于研究阿尔茨海默病和类风湿性关节炎。 | |||
T79157 |
Pimicotinib
ABSK021,ABSK-021 |
c-Fms; Others | Others; Tyrosine Kinase/Adaptors |
Pimicotinib (ABSK021) 为一种有效的 CSF1R 抑制剂,具抗肿瘤活性,可用于研究晚期实体瘤。 | |||
T70444 |
Edicotinib HCl
|
||
Edicotinib, also known as JNJ-40346527, is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. FMS tyrosine kinase inhibitor JNJ-40346527 blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS cannot activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tum... |